New acid blocker may beat standard drug for stomach bug

NCT ID NCT07165444

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two types of acid-reducing drugs—vonoprazan (a newer drug) and rabeprazole (a standard drug)—when used as part of a 10-day combination therapy for H. pylori infection. About 320 adults with confirmed H. pylori will be randomly assigned to one of the two treatments. The main goal is to see which drug leads to higher eradication rates, with fewer side effects and better patient adherence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
vonoprazan (potassium-competitive acid blocker) and rabeprazole (proton pump inhibitor)
What this could lead to
If successful, this could show that vonoprazan is more effective than rabeprazole at eradicating H. pylori when used in combination therapy, potentially improving treatment success rates.
What could go wrong
This is a relatively small, single-center trial. The results may not apply to all populations, and the study does not test long-term outcomes or recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BISMUTH BASED QUADRUPLE THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tanta University

    RECRUITING

    Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.